SARS-CoV-2: Insights from the Immunopathogenesis and Current Clinical Diagnosis and Therapeutic Strategies

Shruti Sharma¹*, Ujjawal Sharma²#, Anupama Chaudhary³, Manisha Naithani⁴, Priyanka Naithani⁴, Saurabh Prasher², Bunty Sharma⁴, Pramod Kumar Nagar⁵, Prudhvi Lal Bhukya⁶, Ummati Bhalerao⁶, Meenakshi Singh⁷, Manjita Srivastava⁸, Munneesh Kumar Barman⁹, Sampan Attri², Jitender Gairolla²,11#

¹Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
²Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India
³Orinvin BioSystems, Karnal, India
⁴Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, India
⁵Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
⁶Chitkara School of Health Sciences, Chitkara University, Punjab, India
⁷Hematology Oncology Unit, Advance Pediatric Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India
⁸National Institute of Virology, Pune, India
⁹National Institute of Virology, Pune, India
¹⁰Transplant Immunology and Immunogenetics Lab [HLA], ACTREC, Tata Memorial Centre
¹¹Laboratory for HIV Research, National Centre for Cell Sciences, Pune-India
¹²Department of Microbiology, All India Institute of Medical Sciences, Rishikesh, India

ABSTRACT

The global public health scenario is worsening gradually as the confirmed cases of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infections are incessantly escalating with every passing day. The pathological condition caused by SARS-CoV-2 is termed as Coronavirus disease 2019 (COVID-19). The understanding of SARS-CoV-2 transmission dynamics, immunopathogenesis, and the need for early-stage diagnosis and the effective therapeutic regime are the few immediate challenges faced by healthcare professionals worldwide. More specifically, the role of SARS-CoV-2 in the host’s immunopathogenesis response is crucial to determine the disease severity and its clinical outcome in COVID-19 patients. In the present review, we provide insights into the SARS-CoV-2 pathology, host immune responses including innate, cellular, and humoral responses, and immunomodulatory functions of SARS-CoV-2 including cytokine storm and immune evasion. We also shed light upon the present clinical and laboratory-based applications enrolled in the SARS-CoV-2 diagnosis. Taking into consideration the pathogenesis and SARS-CoV-2 immune function, in the present review, we finally provide succinct insights into the SARS-CoV-2 transmission dynamics, immunopathogenesis, with the assessment of the current diagnostic and preventive/therapeutic strategies.

Introduction

We are witnessing unprecedented times with the rapidly evolving global COVID-19 pandemic that has brought the world to a socio-economic halt and greatly impacted public health worldwide. The onset of the COVID-19 outbreak was marked in late December 2019, with the reporting of a group of patients suffering from a Severe Acute Respiratory Syndrome-like disease in Wuhan, China. Preliminary investigations revealed that the causative agent is a previously unknown virus and therefore it was named as 'Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), by the ICTV (International Committee on Taxonomy of Viruses)'. Coronaviruses belong to the Coronaviridae family that comprises of viruses which are characteristically identified by a ribonucleic acid core surrounded by a protein-spiked envelope and their structural resemblance to that of a crown (crown i.e., corona in Latin)
has resulted in their nomenclature as coronaviruses. Coronaviruses (CoVs) form a major group of viruses under the Nidovirales order that comprises three families viz. Arteriviridae, Roniviridae, and Coronaviridae. Most coronaviruses are known to produce mild respiratory and occasionally gastrointestinal-related symptoms with the severity of respiratory disease ranging from mild symptoms such as common cold to even severe respiratory complications such as pneumonia.

The earliest case of a common cold due to infection by a coronavirus was reported in 1960. Later in 2001, almost with a gap of four decades, a Canadian study reported flu-like symptoms in about 500 patients, wherein 17-18 cases were found to be infected by a coronavirus. Hence, coronavirus infections were inferred as non-lethal until 2002. However, the outbreak of SARS coronavirus (SARS-CoV) in 2003 attributed to a high mortality rate. Furthermore, another serious coronavirus outbreak was occurred in 2012, in Saudi Arabia due to a new coronavirus named Middle East Respiratory Syndrome Coronavirus (MERS-CoV). After a gap of seven years, a novel coronavirus struck the world again in December 2019, in a different form and identity viz. the SARS-CoV-2. It was traced to be of zoonotic origin with the seafood and live animal market in Wuhan, China being the prime suspected source. On March 11, 2020, the WHO declared the outbreak of Coronavirus Disease-2019 (COVID-19) a ‘pandemic’, with the causative agent, SARS-CoV-2, defying the continental boundaries and spreading globally and North America and Europe being important and vastly affected epicenters. Evidence-based knowledge on COVID-19 has become crucial to get a better understanding of the etiology, immunopathogenesis, and immunomodulatory activities. Timely assessment of these aspects of the SARS-CoV-2 infection could enable us to build efficient clinical diagnostic and preventive/therapeutic regimes against the ongoing fight against this highly transmissible virus. In this review, we shed light upon the SARS-CoV-2 infection/transmission dynamics, hosts innate and acquired immune responses, and its immunomodulatory functions including the commonly witnessed cytokine storm and immune evasion. Furthermore, we discuss the scope of present clinical diagnostic approaches and preventive/therapeutic strategies. The evidence-based new knowledge, as succinctly reviewed in the present report, could essentially pave the way for better and effective diagnosis, management, and prevention of ongoing COVID-19 pandemic.

SARS-CoV-2, Outbreak, and Transmission Dynamics

The first few cases of SARS-CoV-2 infected cases identified infections were reported from in Wuhan City China (in the Hubei Province), with symptoms like province of China and these cases presented with an acute respiratory syndrome of idiopathic etiology. An early outbreak of SARS-CoV-2 infection showed symptoms such as fever, sore throat, and significant dyspnea. On February 11, 2020, WHO named the disease as ‘COVID-19’, and by the end of February, COVID-19 had spread to over 25 nations. An early investigative study performed on the confirmed COVID-19 cases from Wuhan reported the exposure history of the patients to the seafood market. Besides the live-food, the possibility of seafood contamination with bats or bat droppings was also greatly postulated. Initial phylogenetic analyses of SARS-CoV-2 suggested its resemblance to the beta-coronaviruses, however, the distinctive phylogeny of the RNA-dependent RNA polymerase of SARS-CoV-2 indicated that it was a novel strain of the genus Betacoronavirus and subgenus Sarbecovirus. The genomic analyses revealed an 88% sequence identity of SARS-CoV-2 with bat coronaviruses, and therefore affirmed its zoonotic origin with bats serving as reservoirs for SARS-CoV-2, which further transmit the disease to humans and other animal species. Prior to the WHO’s declaration of the ‘COVID-19 pandemic’ in March 2020, an unexpected rise in the numbers of confirmed COVID-19 positive cases were observed in China. An early report from China revealed that the basic reproduction number (R0) of COVID-19 ranges from 2.2 to 3.58 which was relatively lesser than SARS but higher than MERS. Of note, the SARS-CoV-2 median incubation duration was found to be 6.4 days (Credible interval (CI)-95% 5.6 to 7.7 days) and these were very similar to those for MERS and SARS. The key pathology factors such as the onset of symptoms and rate of mortality were found to be dependent on age, pre-conditions (hypertension, diabetes, and cardiovascular disease) and the immune state of the infected individual. Therefore, a higher susceptibility, severity, and mortality rate of COVID-19 was reported in individuals who were either aged (median > 59 years), or had had aforementioned comorbidities. In the early outbreak, the mortality rate was reported to be between 1.5- 3% in Wuhan, China, however, these statistics largely found to depend on the criteria of diagnosis, the scale of COVID-19 transmission, and geographical location as well. By date, the COVID-19 outbreak has spread to over 208 countries, and the Centre for Disease Control and Prevention (CDC) and WHO are jointly engaged in closely monitoring the situation to forecast its timely impact on public health. As of March 20, 2021, a global death count of 2,694,094 with a total 121,969,223 confirmed cases have been estimated and as a result of the COVID-19 pandemic (https://covid19.who.int/). While assessing the SARS-CoV-2 transmission dynamics, the person-to-person contact established either through direct contact or droplets released in the air (by coughing or sneezing) was found to be the most common route of its transmission to a healthy person. While, the indirect routes of transmission were also observed, suggesting that SARS-
SARS-CoV-2 transmission can also occur by touching a surface or fomites (copper, plastic, steel, cardboard, etc.) that contains the existing virus particles\(^{22,23}\). Of note, the half-life of SARS-CoV-2 varies with environmental conditions, and it was notably high on cardboard (~ 24 hours), but found to be at a minimum in aerosols (≤ 4 hours)\(^{23}\).

**SARS-CoV-2 Infection, Host Cell Entry, and Immunological Triggers**

The 50-200 nanometers (nm, diameter) virion of SARS-CoV-2 is found to be composed of 4 structural proteins viz. spike (S) envelope (E), membrane (M), and nucleocapsid (N) (Fig. 1A)\(^ {24,25}\). Out of these, the S protein is essential for attachment of the virus to the membrane of host cells and to gain access into the cells (Fig. 1B)\(^ {24}\). Initial validations conferred that SARS-CoV-2 acquires a greater binding to ACE2 protein in humans which was later identified to be its binding receptor by which it ensures entry inside the cell\(^ {26,27}\). Of note, processing of S-protein by host cell transmembrane proteases serine 2 (TMPRSS2) was found to be crucial for S-protein-ACE2 coupling, wherein the TMPRSS2 protease plays an activator function and facilitates the SARS-CoV-2 entry into the host cell (Fig. 1B)\(^ {27}\). Markedly, this processing of S-protein before its binding to the ACE2 receptor includes its enzymatic modification leading to its cleavage and change in conformation by protease activity of TMPRSS2 that resides in the vicinity of ACE2 receptor i.e., a crucial step in the initiation of viral endocytosis (Fig. 1C)\(^ {28}\). Insights from an earlier report analyzing SARS-CoV binding with ACE2 suggest that it enables SARS-CoV-2 internalization and trafficking into the endosomes and then the lysosomes, which subsequently helps in the viral uncoating and fusion (Fig. 1C)\(^ {29}\). In this process, the S protein further undergoes a series of post translational modifications including enzymatic cleavage and modifications by both cathepsin L and B, the key lysosomal cysteine proteases, which causes the internalization of the virus into the endo-lysosomes. These steps are crucial in the fusion of viral and late endosome membranes and subsequent discharge of the viral genome.

**Figure 1. SARS-COV-2, priming of S-protein, and host cell entry.**

A. SARS-COV-2 virion and its key proteins. B. Schematic diagram showing host cells TMPRSS2-activated binding with SARS-COV-2 S-protein and ACE2 receptor localization at the host cell membrane. C. Schematic diagram mimicking steps for SARS-COV-2 entry into the host cells and enzymatic processing of Spike (S) protein by host Cathepsin L enzyme before releasing its ssRNA genome to the host cells. This pictorial representation relies on the reference information available for SARS-CoV-2 infection.
(ssRNA) in the host cell cytoplasm (Fig. 1C)\textsuperscript{30}. The latter step is highly pH-dependent, where fusion only occurs after reaching highly acidic conditions in the lysosomes, possessing the utmost cathepsin L activity (Fig. 1C)\textsuperscript{31}. These findings are further supported by the observation that the usage of various lysosomotropic agents inhibits infection by interfering with lysosomal processing of viral membrane proteins, which is a pre-requisite for fusion\textsuperscript{32}. Therefore, it is reasonable to speculate that inhibiting the binding of the S protein to ACE2 or intracellular blocking of its subsequent cleavage by cathepsin L could be the two key target steps in the SARS-CoV-2 infection to develop therapeutics against SARS-CoV-2\textsuperscript{30}. Another key therapeutic target could be the Nsp15 protein, which is conserved among coronaviruses and is required for their life cycle and virulence. Nsp15 is a crucial SARS-CoV-2 protein that interferes with the host immune system and facilitates the replication of the virus genome within the host\textsuperscript{33}.

Looking at the immunological cues of the SARS-CoV-2’s viral function, frequent lymphopenia, and pneumonia have been observed in infected moderate-to-severe cases\textsuperscript{34}. Of note, SARS-CoV-2 induced alveolar macrophage activity has been suggested to trigger the immunological response in the patient’s lungs that incites cytokines/chemokines release and causes a subsequent activation of T-Cell and the Neutrophils\textsuperscript{35} (Fig. 2). As a result of this, elevated expressions of pro-inflammatory cytokines viz. TNFα, MCP-1, MIP-1A, IL-2, IL-7, IL-10, and G-CSF were observed in a severely infected cohort of 41 hospitalized COVID-19 patients (Fig. 2)\textsuperscript{17}. These factors suggest a crucial role of cytokine storm leading to viral sepsis and inflammation-induced lung injury. These risks may further promote pneumonitis and acute respiratory distress syndrome (ARDS) that may lead to the organ collapse, shock, and eventually death\textsuperscript{36}. Another report by Liu and Li\textsuperscript{37} suggests that the binding of viral proteins attacks the heme localized on the hemoglobin 1-beta chain to detach the iron and to constitute the porphyrin. The above activity of viral protein attenuates the hemoglobin function to transport oxygen and CO\textsubscript{2}. This also interferes with the heme anabolic pathways of humans resulting in the several debilitating manifestations of COVID-19\textsuperscript{19,37}. A review of SARS-CoV-2’s activity and its impact on the host’s immune system is discussed in detail in subsequent sections.

**SARS-CoV-2 Infection and Immune Response**

Innate immunity plays a crucial role in combating the severity of any viral infection. In a recent study, the innate immune response was shown to cause an increase in the neutrophil count and cause lymphopenia\textsuperscript{38} which indicates its critical role in disease progression and severity. The Severe Acute Respiratory Syndrome caused by contagious SARS-CoV-2 primarily targets the lungs and causes severe clinical manifestations. The frontline complement proteins, type I Interferons (IFN), and other factors of innate immune response essentially control viral replication in the host during the initial stages of the disease itself\textsuperscript{39}. Activation of these factors on viral exposure subsequently triggers and shapes the adaptive immune response. However, an over-activation of innate immune response can result in lethality to host tissues\textsuperscript{40}.

Previously, it has been shown that SARS-CoV attacks T cells. A minimal expression of ACE2 receptor on monocytes/macrophages in the lungs was observed by Dandekar and

---

**Figure 2. SARS-COV-2 Pathogenesis and immunological triggers.** Schematic diagram showing SARS-COV-2 induced immunological trigger which involves its interaction with alveolar macrophages and subsequent activation of T-cells and neutrophils. The right side of the figure depicts SARS-COV-2 entry and release of its ssRNA genome into the host cells.
Perlman⁴¹, which suggests a possibility of the involvement of other immune mechanisms such as antigen-antibody reactions. It is speculated that SARS-CoV-2 may modulate the host innate immune response by dampening the type I IFN response as is often the case in SARS. However, as of now, there is no evidence which indicates a similar mechanism of modulation of host innate immune responses by SARS-CoV-2⁴².

A lot has been learnt regarding the molecular pathogenesis and host immune responses of human coronaviruses from the SARS-CoV epidemic in 2003. Many studies were aimed at understanding the immune response in SARS-CoV infected patients so as to highlight upon the pathogenesis and clinical perseverance of the infection. These efforts to decipher the underlying immune mechanisms have investigated the interaction of SARS-CoV with innate immune cells e.g., dendritic cells (DC), macrophages, and also, their role in triggering other immune cells and responses including phenotype maturation, T-cell priming activity, cytokine production, and phagocytosis. Of note, the activated macrophages and DCs essentially contribute to the maintenance of innate response homeostasis within the host’s lung and inside infected tissues during the course of the infection. During the early phase of the COVID-19 pandemic, the pathology of SARS-CoV-2 was still under investigation, and its molecular pathogenesis and function in host immune response remained largely uncharacterized, and as a result, knowledge of these aspects was majorly derived from the studies that investigated SARS-CoV immunopathogenesis (Fig. 3).

SARS-CoV-2 infections are characterized with a high degree of lymphopenia, which in some cases has been reported to affect CD4+ T cells, CD8+ T cells, B cells and natural killer cells, while other studies indicate that it is more associated with CD8+ T cells. Severe cases of COVID-19 also show a marked increase in the levels of cytokines such as IL-6, IL-10 or tumor necrosis factor...
(TNF), which are known to have a direct effect on T cells as well as DCs and neutrophils. T cell depletion may also be a result of hyperactivation or even the excessive expression of pro-apoptotic factors such as FAS, TRAIL or caspase 343.

The CD8+ T cell response in COVID-19 has been observed to vary within and among cohorts as well. Terminally differentiated or exhausted T cells have been associated with certain cases of severe COVID-19 owing either to an increased expression of the inhibitory receptors PD1, TIM3, LAG3, CTLA4, NKG2A and CD39, or as a result of hyperactivation, or in some cases, a result of decrease in the expression of inhibitory receptors has also been observed. In comparison with CD8+ T cell activation, CD4+ T cell activation is lesser. However, CD4+ responses are associated with worse clinical outcome in patients. SARS-CoV-2 S protein specific CD4+ T cells have a T5₁ cell profile, and they have the ability to produce IFNγ, while the role of T5₁ cells in COVID-19 is less clearly understood as of yet43.

SARS-CoV-2 and Innate Immune Response

Attenuation of type 1 IFN response

Host interferons (IFN) are well-known to interfere with viral life cycle and limit their replication by activating several hosts antiviral effectors proteins such as Protein kinase R (PKR), RNase L and other factors of innate response, but prior studies on SARS-CoV encoded proteins have been described to attenuate the IFN mediated antiviral signalling by inhibiting the IFN activity (Fig. 3)44. In the early phase of the SARS-CoV-2 pandemic, these insights on coronaviruses in general, included the SARS- and MERS-CoVs is what provided basic conceptual as well as speculative knowledge regarding the novel virus. The SARS-CoV nsp1 protein inhibits IFN function by modulating STAT phosphorylation, and a similar control over IFN activity has been observed by nsp3 involving unknown mechanisms. The IFN response blockade by SARS-CoV membrane (M) and nucleocapsid (N) structural proteins has also been shown to be mediated by TBK1/IKK through an unknown mechanism. The IFN response blockade by SARS-CoV membrane (M) and nucleocapsid (N) structural proteins has also been shown to be mediated by TBK1/IKK through an unknown mechanism. Of note, attenuation of IFN production and/or function by the SARS-CoV structural and non-structural proteins activates inflammatory signalling, essentially by the progressive viral replication in host cells induced by Pathogen-Associated Molecular Patterns (PAMPs). The PAMP machinery in turn attenuates IFN function and elicits pattern recognition receptors (PRRs) promoting an inflammatory response. Deficiency of IFN response elevates counts of Ly6C low monocytes and neutrophils18,45 (Fig. 3). These aspects of SARS CoV pathogenesis and immune evasion were speculated to apply to SARS-CoV-2 as well.

With increasing research on the novel SARS-CoV-2, a better understanding of its immune mechanisms has been obtained. Being an RNA virus, upon cellular entry, several of the SARS-CoV-2 proteins have the ability to interact with and bind to RNA, even that of host origin. Banerjee et al. shed light upon the molecular basis of SARS-CoV-2 pathogenesis describe the ability of SARS-CoV-2 proteins to interact with human RNAs. They identified a very specific interaction between the viral Nsp16 protein- which localizes in the nucleus upon infection, and the U1 and U2 snRNAs which mediate post-transcriptional RNA splicing, and in doing so, Nsp16 has the ability to suppress global mRNA splicing in SARS-CoV-2 infected cells so as to decrease host protein and mRNA levels by triggering nonsense-mediated decay of improperly spliced mRNAs. This mechanism may result in inhibition of IFN-mediated immune responses since most of the key genes for IFN stimulation are spliced post-transcriptionally. Additionally, the SARS-CoV-2 Nsp1 binds to 18S ribosomal RNA in the mRNA entry channel of the 40S subunit and disrupts translation of RNA with an ability to suppress translation of global host mRNAs and the host IFN immune response. Similarly, Nsp9 and Nsp9 bind to the 7SL RNA component of the SRP (signal recognition peptide) preventing its proper folding and assembly which further suppresses the integration of integral membrane proteins in the cell membrane. A very interesting finding by Banerjee et al. was that these four viral proteins are all products of the initial stages of the virus replication cycle prior to production of the viral dsRNA which is a trigger for the type I IFN response, and this disruption of cellular processes is what allows the virus to replicate with a minimization in the IFN-mediated immune response66.

Additionally, Nsp6 interferes with IFN-I production by binding TANK binding kinase 1 (TBK1) to suppress IRF3 phosphorylation. Nsp13 and Nsp15 bind and block TBK1 phosphorylation. The ORF6 localizes at the nuclear pore complex (NPC), binds importin karyopherin-α2 (KPN2A) to target the nuclear import pathway and inhibit the IRF3 nuclear translocation. Several SARS-CoV-2 proteins also have the ability to block STAT1/STAT2 phosphorylation. Nsp1, nsp6, nsp13, ORF3a, M, and ORF7b can inhibit STAT1 phosphorylation and ORF6 blocks STAT1 nuclear translocation, while nsp6, nsp13, ORF7a, and ORF7b prevent STAT2 phosphorylation47.

SARS-CoV-2 and altered Macrophages and Dendritic cell immune function

Neither DCs nor MP cells were shown to acquire SARS-CoV infection, or even facilitate viral replication. However, reports have shown that exposure to the infectious SARS-CoV acquires phenotypic and functional changes in the DC and macrophages (Fig. 3). These changes alter differentiation of the DCs and modulate the expression of co-stimulatory molecules required for priming of T-cells, which serves as an important factor for stimulating the subsequent adaptive immune response. Exposure of infectious SARS-
CoV was earlier shown to attenuate the antigen-capture function of macrophages, wherein endocytosis uptake gets disrupted. This, in turn, substantially compromises the antigen presentation function of macrophages to T-cells. On the other hand, exposure of differentiated DCs to infectious SARS-CoV results in exponentially higher activation of the T-cells by these cells. These results offer insights into the immunomodulatory function of SARS-CoV in the innate immune cells that further determine the adaptive response in the event of SARS-CoV infections (Fig. 3) [56, 57].

In the case of SARS-CoV-2, alveolar macrophages are most likely the very first immune cells that are encountered by the virus during infection. A study by Dalskov et al. indicates that naïve alveolar macrophages are incapable of sensing SARS-CoV-2 and mounting an IFN response against the virus, which suggests that SARS-CoV-2 genomic RNA is not detected by alveolar macrophages and this is a postulated reason for the early asymptomatic phase of COVID-19. This is very much in contrast to the response mounted by alveolar macrophages against other respiratory viruses such as the Influenza virus and the Sendai virus. However, Dalskov et al. noted that similar to SARS and MERS, SARS-CoV-2 was incapable of causing productive infections in alveolar macrophages [58].

Dysregulated cytokine and chemokine levels and its clinical consequences

The attenuated type 1 IFN action, as discussed earlier, compromises early viral control. Additionally, the SARS-CoV replication rate in ACE1/1 human lung epithelial cells are very rapid. Therefore, these factors potentially result in hyperactivation of dendritic cells and macrophages, aggrandizing the proinflammatory responses of these innate immune cells (Fig. 3). Additionally, elevated expressions of IFN-γ, IL-1, IL-6, IL-12, and TGFβ pro-inflammatory cytokines and CCL2, CXCL10, CXCL9, and IL-8 chemokine were observed in the blood serum of severely-sick SARS-CoV patients as compared to patients having moderate symptoms (Fig. 3) [59, 60]. Studies have shown a significant increase in levels of pro-inflammatory cytokines (PICs) such as IL-2, IL-7, CRP, IP-10, MCP-1, TNF-alpha – all further validating the presence of a modulated, hyperactive innate immune response in SARS-CoV infected patients [59, 60]. A clinical outcome of the release of PICs in SARS-CoV-infected ACE2+ cells in patient tissues was suggested to promote acute lung injury and multi-organ failure (Fig. 3). For instance, MCP-1 functions in the induction of the migration of macrophages/monocytes and potentiate these cells in the vascular system to travel to the infested area/tissue to ensure their combative function against the viral agent(s). However, the combative function of these cells is not limited to infected cells only, thus it can also harm normal cells that are in close affinity. In severe SARS-CoV cases, it has been consistently found that there is a higher infiltration of monocyte-macrophages-neutrophils at the site of infection. This provides a framework for understanding the pathogenesis of SARS-CoV infection. Some PICs e.g., TNF-α, TGF-β1, etc. producing macrophages undergo proliferation and become activated, resulting in a higher PICs release, causing more damage of the host tissues [61]. Expression of Mac387+ and CD25+ proliferation and/or activation markers on a large number of alveolar macrophages corroborates these results. However, TGF-β1 has been implicated in alveolar epithelial cell death and this may promote Fas-mediated cell death of platelets and lymphocytes as well. These TGF-β1 function may produce acute lung injury, thrombocytopenia, and lymphopenia in SARS-CoV patients. Expression levels of apoptotic Fas and Fas Ligand (FasL) remain high in pneumocytes and epithelial cells of the lungs of SARS patients [53, 56, 57].

SARS-CoV-2 infection and Antigen Presentation

Antigen presenting cells (APCs) are the host’s major anti-viral defense mechanism that process and present the antigen when pathogens strike into cells. The major histocompatibility complex (MHC) or human leukocyte antigen (HLA) presents the antigenic peptides that are primarily recognized by cytotoxic T lymphocytes (CTLs) (Fig. 3). Although, the process of antigen presentation remains highly conserved and demonstrates mechanistic uniformity for diverse viral infections, lack of any evidence of these mechanisms in SARS-CoV-2 presently hindered a clear view. The gathered knowledge on SARS-CoV and MERS-CoV for their antigen presentation mechanisms offers an insight into these functions for SARS-CoV-2 (Fig. 3). The coronavirus antigen presentation is mostly governed by MHC I molecules [62], but then MHC II similarly subsidizes to antigen presentation.

Early reports have shown that several HLA allelic polymorphisms including HLA-DR B1*1202, HLA-B*0703, HLA-B*4601, and HLA-Cw*0801 are associated with vulnerability to SARS-CoV, however, three alleles viz. the HLA-A*0201, HLA-DR0301, and HLA-Cw1502 are also associated with host’s defense mechanism against the SARS-CoV infection [63]. Reports examining the MHC II polymorphisms in MERS-CoV infection revealed that antigen presented by two MHC II molecules viz. HLA-DQB1*02:0 and HLA-DRB1*11:01 contributes to the vulnerability to MERS-CoV [64]. Moreover, polymorphisms of antigen presentation related mannose-binding lectin (MBL) gene were found to be predictive of a greater risk of SARS-CoV disease [65].

SARS-CoV-2 and Cellular and Humoral Immunity

Antigen presentation consequently activates the cellular and humoral immune response in the host, which is primarily triggered by viruses targeting B- and T- cells. The immunoreactive antibodies against SARS-CoV show a
characteristic IgM pattern that disappears at the end of the 12th week, while IgG antibodies stay in the humoral system for a long time. The IgG antibodies showing specificity to SARS-CoV mainly includes the S- and N-specific antigen. A recent report showed the counts of CD4+ and CD8+ T lymphocytes significantly reduce in the blood along with the peripheral blood mononuclear cells (PBMCs) in COVID-19 patients, however, these cells showed a hyper-activated state as marked by high expression of HLA-DR (CD4+) and CD38 (CD8+) dual positive populations. Severely infected SARS-CoV patients were also earlier shown to have a depletion of CD4+ and CD8+ T cells population. Of note, in the survived SARS-CoV patients, the CD4+ and CD8+ memory T cells population was present for about four years and has actively acquired DTH response, proliferation, and IFN-γ production. A study conducted by Tang et al., showed that memory T cells retain SARS-CoV S-peptide specific memory even after six years of the viral infection that was found to be evident in 14 out of 23 patients. Similarly, a potent activity of CD8+ T cells was also validated in the mice model for the clearance of MERS-CoV viral load. These evidences could provide a valuable reference to assess the host’s immune response against the SARS-CoV-2 in current clinical settings.

SARS-CoV-2 Immunogenicity and Cytokine Storm

Development of ARDS largely contributes to the mortality in COVID-19 patients. Huang et al. have shown that 6 out of 41 SARS-CoV-2 patients died of ARDS. ARDS is a frequent immunopathological response as is evidently seen in consecutive coronavirus infections. An activated systemic inflammatory response in COVID-19 patients prompts an array of pro-inflammatory chemokines and cytokines that contributes to the emergence of a robust cytokine storm in the patients. It includes the constitutive release of IFN-α, IFN-γ, TNF-α, IL-1β, IL-6, IL-12, IL-18, IL-33, and TGF-β pro-inflammatory cytokines and CXCL9, CXCL10, CCL2, CCL3, CCL5, CXCL8, chemokines (Fig. 3). Consistent to these findings in COVID-19, patients with severe MERS-CoV infections exhibited a higher level of pro-inflammatory cytokines and chemokines in the serum, in comparison to those who had moderate infection. The clinical feature of cytokine storm involves aggressive assault of the immune system in the host body that leads to ARDS and multiple organ failures and eventually contributes to mortality in severely infected SARS-CoV2 patients, as also reported earlier in MERS and SARS-CoV pathologies.

SARS-CoV-2 and Immune Evasion

MERS and SARS coronaviruses evade the host immune system to promote their replication and survival. Microbe-derived molecules/motifs viz. PAMPs (Pathogen-associated molecular pattern) are largely recognized by pattern recognition receptors (PRRs) or toll-like receptors (TLRs) that further affirms the response of the host’s immune system. MERS and SARS coronaviruses were shown to instigate the formation of double-membrane vesicles, lacking PRR that facilitates their replication in the vesicles and escaping from the host identification of their dsRNA. Interferon-1 (IFN-1) provides protection to host against viral infection, however, inhibition of its above function was observed in MERS-CoV and SARS-CoV infected mice. The role of MERS-CoV accessory protein 4a was suggested earlier to inhibit IFN activation. In a similar manner, MERS-CoV virus membrane antigens ORF4a, ORF4b, and ORF5 were seen to restrict IFN regulatory factor 3 (IRF3) nuclear localization that subsequently impairs IFN promoter activation. These findings emphasized the importance of building preventive/therapeutic strategies that could target the immune evasion function of SARS-CoV-2.

COVID-19 Diagnostics: Clinical and Laboratory Approaches

In clinical diagnosis, patient history is designated as an essential primary record. Prior to an advancement in the stage of this pandemic and the diagnosis of infection, patient history, in terms of contact with suspected or confirmed COVID-19 cases, supported quicker diagnosis for COVID-19. At the physiological level, mild-moderate fever, coughing/sore throat, and shortening of breath are primary symptoms of SARS-CoV-2 infection patient. Nevertheless, reports have shown that SARS-CoV-2 may persist in asymptomatic people for more than two weeks and there are chances of its recurrence after recovery as well. The infected individual, at an early stage, may possess an average or reduced count of peripheral white blood cells (WBCs). A recent clinical study, comprising a 1,099 COVID-19 patient’s cohort exhibited a lesser than 4×10^9/L WBC count. Also, most of the COVID-19 patients were found to have elevated enzymes, proteins like C-reactive protein (CRP), aspartate aminotransferase (AST), myoglobin, and erythrocyte sedimentation rate. As a preferred clinical diagnosis method, analyses of chest X-ray of a majority of COVID-19 patients has revealed an abnormal state of the lungs, marked by shadows in small patches and interstitial changes that are excessively evident in the extrapulmonary bands. Furthermore, Computed Tomography (CT) of the chest in COVID-19 patients showed several extended ground-glass opacities and infiltrations with the progression of infection’s severity. Often, patients with COVID-19 infection exhibit acute lung injury, unusual pneumonia, and ARDS. At the advanced stage, increased inflammation, accumulation of fluid, and advanced fibrosis in the COVID-19 patient’s lungs was shown to compromise the gas exchange and thus may postulate an eventual organ failure. Therefore, a greater abnormality in chest
radiographic scans could predict a more severity of the COVID-19 infection in the patient.

Quantification of COVID-19 nucleic acid in nasopharyngeal and oropharyngeal swab sample or secretion of the respiratory tract sample by quantitative Reverse Transcription- Polymerase Chain Reaction (RT-qPCR) is the routine diagnostic approach enrolled presently in the laboratories worldwide (Fig. 4). RT-qPCR remains the gold standard and sensitive tool for COVID-19 detection in comparison to other available symptomatic and scanning tests as it directly detects the SARS-CoV-2 genetic signature (RNA) and quantifies the viral load. Therefore, RT-qPCR offers enormous help to clinicians and epidemiologists to trace COVID-19 spread either to individual clusters or in the community, and for its clinical management as well. The RT-qPCR test includes primer and probe designing at initial steps followed by the optimization of the amplification conditions, while modification in processing steps and duration can be conceived based on manufacturer’s recommendation. Primers and probe for RdRP (RNA-dependent RNA polymerase) gene of the ORF1ab region of open reading frame and E (Envelope -protein) gene have shown high analytical sensitivity. As an early readout of RT-qPCR utility, initial reports from China revealed that its overall detection rate for SARS-CoV-2 infection was 38% in 4880 cases, while other testing performed on 51 confirmed patients of SARS-CoV-2 infection showed 71% positive detection rate. It has been observed that patients may show COVID-19 positive in the RT-qPCR test after 2-8 days of getting infected. Some modified methods of RT-qPCR test known as Reverse Transcription Loop-mediated isothermal amplification (RT-LAMP) and CRISPR-Cas12-based assay for SARS-CoV-2 RNA detection were also developed and enrolled for diagnosis. Consistent to these novel diagnostic initiatives and with evolving situation in the United States, the FDA (Food and Drug Administration, USA) has recently approved the emergency usage authorization of cobas 6800/8800 high throughput platforms for SARS-CoV-2 diagnosis which offer quality and high-volume testing capacity. High-throughput sequencing for SARS-CoV-2 nucleic acid and SARS-CoV-2 specific antibody-based ELISA systems have now been employed as point-of-care tests (POCT) for rapid SARS-CoV-2 diagnosis (Fig. 4).
Preventive and Therapeutic Strategies

Presently, we lack any SARS-CoV-2-specific therapeutics that could offer a sure shot clinical outcome. Researchers and health professionals across the globe are summing up their efforts to identify and validate precise SARS-CoV-2 targeted therapeutics. Earlier, WHO had released technical guidance systematically listing the crucial measures to contain and further prevent COVID-19 spread\(^96\). It broadly specifies the strategic measures to prevent infection in healthcare professionals and related facilities and extensively discusses quarantine measures and requisite of rational use of masks and personal protective equipment.

### Table 1. Evidence-based details of recent and priorly utilized and available potential therapeutic possibilities to cure COVID-19.

| Type of Drug | Drug or Molecule | Current Use | Mechanism and Current status | References |
|--------------|-----------------|-------------|-------------------------------|------------|
| Anti-malarial agent | Chloroquine Phosphate & Hydroxchloroquine sulfate | Malaria Treatment | Anti-malarial agent Effective against viral entry & killing through photolytic processing Not recommended for COVID-19 therapy any longer. | \([14,108]\) |
| Anti-Viral Agents | Remdesivir | Ebola Virus Treatment | Nucleotide analogue Approved for COVID-19 therapy | \([109]\) |
| | Ritonavir &Lopinavir | HIV Treatment | Protease inhibitor Shown in vitro activity against other coronaviruses No treatment benefit observed in initial randomized, controlled, open-label trial for COVID-19 patients | \([100,102,110]\) |
| | Favipiravir (T-705) | Influenza treatment | RNA polymerase inhibitor thus inhibits virus replication Has broad spectrum anti-viral activity Tested in clinical trial | \([100,111]\) |
| | Ribavirin | Treatment of Respiratory syncytial virus | Inhibits viral RNA-dependent RNA Polymerase Used in the treatment of other coronaviruses Under screening and development | \([109,112]\) |
| | Umifenovir (Arbidol) | Influenza Treatment | Inhibits viral S Protein & ACE2 interaction Repurposed for COVID treatment and being tested in clinical trial | \([113]\) |
| Antibodies | Tocilizumab (Actemra) | Treatment of Rheumatoid Arthritis | Monoclonal antibody for IL-6 receptor Under testing in clinical trial | \([114]\) |
| | Antibody CR3022 | Neutralizing Antibody | Neutralizing Ab, target- viral (SARS-CoV) receptor-binding domain (RBD) isolated from convalescent plasma of COVID-19 patients | \([115]\) |
| Interferon | IFN-α2b | Hepatitis C | Type I interferon Tested in clinical trial | \([111]\) |
| Future Drug Targets | Proteins | Non-structural proteins (nsp10/nsp16) | Under development Inhibitor of Viral Scaffolding and RNA synthesis Under screening and development | \([116]\) |
| | mRNA vaccine | Anti-viral vaccine (mRNA-1273) | Authorized for use Messenger RNA (mRNA) Authorized for use | \([99,101]\) |
| | Herbal | Herbal treatments | Influenza A treatment SARS-CoV treatment | Chinese traditional medicine Under screening and development | \([117, 118]\) |
| | Antibodies | Monoclonal antibody therapy Convalescent sera from priorly infected patients | SARS-CoV treatment COVID-19 therapy Anti-SARS-CoV-2 &anti-ACE2 monoclonal antibodies Under screening and development Currently being used for treatment. | \([25,99]\) |
| | Enzymes | Soluble angiotensin-converting enzyme 2 | Under development Soluble recombinant ACE2 protein Under screening and development | \([119]\) |

#Other potential sources of information are-
1. https://clinicaltrials.gov
2. https://www.who.int/ictrp/en/
3. https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials
4. WHO landscape analysis of therapeutics for coronavirus as on 21st March 2020
One of the broad-spectrum antiviral drugs like HIV protease inhibitors and nucleoside were repurposed and are also being utilized as therapeutic alternatives given their benefits against other earlier reported 2 viral infections. As of recent data, more than 85% percent of patients in China received various anti-viral agents including oseltamivir, ganciclovir, and lopinavir/ritonavir. Another study showed that repurposing of remdesivir could help in COVID-19 treatment, and this drug has been approved for the same. Additionally, a recent report discussed benefits of early-stage intravenous glucocorticoid administration (methylprednisolone, 40–80 mg, given once a day till 5 days), while its treatment course can be modified based on clinician’s recommendation. Furthermore, immune suppressants were recommended to all patients undergoing diagnosis of accompanying hyper-inflammation. Another insightful report citing readouts of multi-centric clinical trials in China demonstrated that chloroquine phosphate i.e., a drug used for malaria treatment, exhibits a clear efficacy and protection against COVID-19-associated pneumonia. FDA’s recent approval to use convalescent plasma (collected from COVID-19 exposed patients) also gave a remedial hope to critically ill COVID-19 patients. Presently, a few potential therapies have been developed for treatment, one such example is the IL-6 receptor blockade. Additionally, a recent report discussed benefits of early-stage intravenous glucocorticoid administration (methylprednisolone, 40–80 mg, given once a day till 5 days), while its treatment course can be modified based on clinician’s recommendation. Furthermore, immune suppressants were recommended to all patients undergoing diagnosis of accompanying hyper-inflammation. Another insightful report citing readouts of multi-centric clinical trials in China demonstrated that chloroquine phosphate i.e., a drug used for malaria treatment, exhibits a clear efficacy and protection against COVID-19-associated pneumonia. FDA’s recent approval to use convalescent plasma (collected from COVID-19 exposed patients) also gave a remedial hope to critically ill COVID-19 patients. Presently, a few potential therapies have been developed for treatment, one such example is the IL-6 receptor blockade. In this line, China has initiated multi-centric, randomized controlled trials to use tocilizumab for COVID-19 patients who are having pneumonia and elevated IL-6 levels.

Table 2. Details of available vaccine and technology used in development as therapeutic possibilities to cure COVID-19.

| S. No. | Vaccine | Vaccine developer | Technology |
|-------|---------|------------------|------------|
| 1.    | (Ad5-nCoV Convidicea) | CanSino Biologics, Institute of Biotechnology of the Academy of Military Medical Sciences, China | Adenovirus vector vaccine (recombinant adenovirus type 5 vector) |
| 2.    | BBIBP-CorV | Sino pharma Institute of Biological Products, Wuhan Institute of Biological Products, China | SARS-CoV-2 vaccine (vero cells) |
| 3.    | BBV152 (Covaxin) | Bharat Biotech, Indian Council of Medical Research, India | Inactivated SARS-CoV-2 vaccine |
| 4.    | CoronaVac | Sinovac, China | Inactivated SARS-CoV-2 vaccine |
| 5.    | CoviVac | The Chumakov Centre at Russian Academy of Sciences, Russia | Inactivated SARS-CoV-2 vaccine |
| 6.    | EpiVacCorona | Vector Institute, Russia | Peptide vaccine |
| 7.    | Johnson & Johnson COVID-19 vaccine | Janssen Pharmaceutica (Johnson & Johnson), BIDMC, Netherlands, United States | Adenovirus vector vaccine (adenovirus serotype 26) |
| 8.    | Moderna COVID-19 vaccine | University of Oxford, AstraZeneca, CEPI, United Kingdom | Adenovirus vector vaccine (modified chimpanzee adenovirus vector, ChAdOx1) |
| 9.    | Pfizer–BioNTech COVID-19 vaccine | Pfizer–BioNTech United States, Germany | RNA vaccine (modRNA encapsulated in lipid nanoparticles) |
| 10.   | Sputnik V COVID-19 vaccine | Gamaleya Research Institute of Epidemiology and Microbiology, Russia | Adenovirus vector vaccine (recombinant adenovirus type 5 and 26 vector) |
| 11.   | ZyCoV-D | Cadila Healthcare, India | DNA vaccine (plasmid expressing SARS-CoV-2 S protein) |
|      | CoVLP | Medicago, GSK, Canada, United Kingdom | Virus-like particles (recombinant, plant-based with AS03) |
Other therapeutic options include the usage of specific cytokine blockade by toclizumab or anakinra and through JAK inhibition (Available at https://www.clinicaltrials.gov/ct2/show/NCT04322773; accessed on 16 April 2020). Currently, unprecedented research efforts towards finding the treatment possibilities for COVID-19 have been made and key recommendations are constantly updated worldwide. Evidence-based details of recent potential therapeutic strategies for COVID-19 cure are duly enlisted in Table 1 and details of vaccines and technology used are duly listed in table 2.

Conclusion

In the present review, we have provided insights into the SARS-CoV-2 pathology by shedding light on the host’s immune function comprising innate, cellular, and humoral responses. Further, we discussed the immunomodulatory functions of SARS-CoV-2 including cytokine storm and immune evasion. The review further sheds light on the clinical and laboratory strategies that are presently employed for COVID-19 diagnosis. We herein provide a detailed and up-to-date insight into the preventive and mitigating measures that are presently being considered against COVID-19 globally. The updates on the repurposing of FDA approved drugs to cure COVID-19 have been highlighted and reflect state of ongoing research and therapeutic initiatives those are being employed worldwide towards finding the treatment strategies for COVID-19. Furthermore, it conferred an update on revised diagnostic state and strategies for accelerated detection of COVID-19 infection. The ongoing clinical trials and research worldwide to develop the interventional COVID-19 treatment have been specifically envisaged. Given the fact that being a scientific community, we are now engaged in translating the health implications of ongoing COVID-19 pandemic, an extensive research further is required to address the challenges of COVID-19 pandemic with identifying the druggable targets, vaccine development, quicker diagnosis, overcoming the acute immune-response linked with SARS-CoV-2 infection.

Declaration of competing interest

The authors declare no conflicts of interest.

Funding

Nil

References

1. Wu Y, Ho W, Huang X, et al. SARS-CoV-2 is an appropriate name for the new coronavirus. Lancet. 2020; 395: 949-950.
2. Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016; 3: 237-261.
3. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Mil Med Res 2020; 7: 1-10.
4. Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. Proc Society Exp Biol Med 1966; 121: 190-193.
5. Holmes KV. SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 2003; 111: 1605-1609.
6. Skowronski DM, Astell C, Brunham RC, et al. Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med 2005; 56: 357-381.
7. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015; 386: 995-1007.
8. Jandric P. Postdigital Research in the Time of Covid-19. Postdigit Sci Edu 2020; 2: 233-238.
9. Lu H, Stratton CW, Tang YW. Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle. J Med Virol 2020; 92: 401-402.
10. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-513.
11. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565-74.
12. Hui DS, Azhar EI, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest novel coronavirus outbreak in Wuhan, China. Int J of Infect Dis 2020; 91: 264.
13. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020; 2020: 102433.
14. Pang J, Wang MX, Ang IYH, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel Coronavirus (2019-ncov): a systematic review. J Clin Med 2020; 9: 623.
15. Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020; 2020: 105924.
16. Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577-582.
17. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med 2020; 382: 1199-1207.
18. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.
19. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91-95.
20. Adhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty 2020; 9: 1-12.
21. Fauci AS, Lane HC, Redfield RR. Covid-19—Navigating the Uncharted. Mass Medical Soc; 2020.N Engl J Med 2020; 382: 1268-1269.
22. Cai J, Sun W, Huang J, et al. Indirect Virus Transmission in Cluster of COVID-19 Cases, Wenzhou, China, 2020. Emerg Infect Dis 2020; 26: 1343-1345.
23. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Eng J Med 2020; 382: 1564-1567.
24. Moussaizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect 2020. doi.org/10.1016/j.jmii.2020.03.022
25. Shankumaraj B, Sirivuttananon K, Wangkanont K, et al. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol 2020; 38: 10-18.

26. Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46: 586-590.

27. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-280.

28. Reinkie LM, Spiegel M, Piege T, et al. Different residues in the SARS-CoV spike protein determine cleavage and activation by the host cell protease TMPRSS2. PLoS One 2017; 12: e0179177.

29. Deshotes MR, Xia H, Srimulana S, et al. Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin ii type i receptor-dependent mechanism. Hypertension 2014; 64: 1368-1375.

30. Shah PP, Wang T, Kaletsky RL, et al. A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells. Mol Pharma 2018; 78: 319-324.

31. Mingo RM, Simmons JA, Shoemaker CJ, et al. Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step. J Virol 2015; 89: 2931-2943.

32. Wang H, Yang P, Liu K, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res 2009; 19: 290-301.

33. Kim Y, Jedrzejczak R, Maltese N, et al. Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. P Natl Acad Sci 2020. doi: org/10.1073/pnas.2003873.

34. Han JFW, Yuan S, Sok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395: 514–523.

35. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. ViriSin 2020. Preprint.

36. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061–1069.

37. Liu W, Li H. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism. ChemRxiv. 2020. Preprint.

38. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270–273.

39. Katze MG, He Y, Gale M. Viruses and interferon: a fight for supremacy. Nature Rev Immunol 2002; 2: 675-687.

40. García-Sastre A, Biron CA. Type 1 interferons and the virus-host relationship: a lesson in detente. Science 2006; 312: 879-882.

41. Dandekar AA, Perlman S. Immunopathogenesis of coronavirus infections: implications for SARS. Nature Rev Immunol 2005; 5: 917-927.

42. Promptchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38: 1-9.

43. Chen Z & Wherry EJ. T cell responses in patients with COVID-19. Nature Reviews Immunology 2020; 20.

44. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Ann Rev Biochem 1998; 67: 227-264.

45. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. In: Sem in Immunopath 2017; 39: 529-539.

46. Banerjee AK, Blanco MR, Bruce EA, et al. SARS-CoV-2 disrupts splicing, translation, and protein trafficking to suppress host defenses. Cell 2020; 183(5): 1325-1339.

47. Quarleri J, Delpino MV. Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host induced factors. Cytokine & Growth Factor Reviews 2021.

48. Yilla M, Harcourt BH, Hickman CJ, et al. SARS-coronavirus replication in human peripheral monocyes/macrophages. Viruses Rev 2005; 107: 93-101.

49. Tseng CTK, Tseng J, Perrone L, et al. Apical entry and release of severe acute respiratory syndrome-associated coronavirus in polarized Calu-3 lung epithelial cells. J Virol 2005; 79: 9470-9479.

50. Dalskov L, Møhlenberg M, Thyrsted J, et al. SARS-CoV-2 evades innate immune detection in alveolar macrophages. EMBO reports 2020; 21(12): e51252.

51. Chong CY, Poon LL, Ng IH, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol 2005; 79: 7819-7826.

52. Law HKW, Chong CY, Ng HY, et al. Chemokine up-regulation in sarscoronavirus-infected, macrophage-derived human dendritic cells. Blood 2005; 106: 2366-2374.

53. Hayden FG, Fritz R, Lobo MC, et al. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 1998; 101: 643-649.

54. Theron M, Huang KJ, Chen YW, et al. A probable role for IFN-γ in the development of a lung immunopathology in SARS. Cytokine 2005; 32: 30-38.

55. Jiang Y, Xu J, Zhou C, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med 2001; 171: 850-857.

56. Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360: 1831-1837.

57. Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. The Lancet 2020; 395: 1517-1520.

58. Liu J, Sun Y, Ji Q, et al. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J Infect Dis 2010; 202: 1171-1180.

59. Kiechho N, Itoyama S, Kashihawa K, et al. Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population. Human Immunol 2009; 70: 527–531.

60. Wang SF, Chen KH, Chen M, et al. Human-leukocyte antigen class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection. J Am Med Assoc 2001; 285: 1502–1506.

61. Hajeer AH, Balbyhy L, Johani S, et al. Association of human; leukocyte antigen class II alleles with severe Middle East respiratory syndrome-coronavirus infection. Annals Thorac Med 2016; 11: 211.

62. Tu X, Chung WP, Zhai Y, et al. Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection. J Infect Dis 2015; 71: 101-109.
105. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14: 72-73.

106. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 2020; 368: 1256.

107. Mehta R, McAuley DF, Brown M, et al. Across Speciality Collaboration, COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033.

108. Huang M, Tang T, Pang P, et al. Treating COVID-19 with chloroquine. J Mol Cell Biol 2020; 12: 322-325.

109. Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 2020; 34: 101615.

110. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Eng J Med 2020; 382: 1787-1799.

111. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Therap 2020; 14: 58-60.

112. Foolad F, Aitken SL, Shigle TL, et al. Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients. Clin Infect Dis 2019; 68: 1641-1649.

113. Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Revista Panamericana de Salud Pública 2020; 44: e40.

114. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences 2020; 117: 10970-10975.

115. Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 2020; 368: 630-633.

116. Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmacologica Sinica B. 2020.

117. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020; 14: 69-71.

118. Yang Y, Islam MS, Wang J, et al. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci 2020; 16: 1708.

119. Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci 2020; 134: 543-545.